Cargando…

Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways

BACKGROUND: Paclitaxel (PTX) resistance is a major obstacle in the treatment of triple-negative breast cancer (TNBC). Previously, we have reported that interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream pathways are associated with PTX resistance in TNBC cells. In this study, we s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Panpan, Song, Dan, Wan, Danhong, Li, Lingyu, Mei, Wenhui, Li, Xiaoyun, Han, Li, Zhu, Xiaofeng, Yang, Li, Cai, Yu, Zhang, Ronghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275687/
https://www.ncbi.nlm.nih.gov/pubmed/32547883
http://dx.doi.org/10.7717/peerj.9281
_version_ 1783542837937176576
author Wang, Panpan
Song, Dan
Wan, Danhong
Li, Lingyu
Mei, Wenhui
Li, Xiaoyun
Han, Li
Zhu, Xiaofeng
Yang, Li
Cai, Yu
Zhang, Ronghua
author_facet Wang, Panpan
Song, Dan
Wan, Danhong
Li, Lingyu
Mei, Wenhui
Li, Xiaoyun
Han, Li
Zhu, Xiaofeng
Yang, Li
Cai, Yu
Zhang, Ronghua
author_sort Wang, Panpan
collection PubMed
description BACKGROUND: Paclitaxel (PTX) resistance is a major obstacle in the treatment of triple-negative breast cancer (TNBC). Previously, we have reported that interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream pathways are associated with PTX resistance in TNBC cells. In this study, we sought to investigate the combination treatment of ginsenoside panaxatriol (GPT), one of the main active components in Panax ginseng, with PTX on viability and apoptosis of TNBC PTX resistant cells, and explore the role of IRAK1 mediated signaling pathways in the therapeutic effects. METHODS: CellTiter-Glo and colony formation assays were used to assess cell viability. Flow cytometry was used to analyze subG1 and apoptosis. Western blot was used to detect expressions of proteins involved in apoptosis and the IRAK1/NF-κB and ERK pathways. The mRNA expression of inflammatory cytokines, S100A7/8/9 and cancer stem cell (CSC)-related genes were examined by qPCR. Stem cells were identified by tumor sphere assay. Cell invasion ability was examined by transwell assay. RESULTS: We show that GPT inhibits MDA-MB-231 PTX resistant (MB231-PR) cell viability in a dose-dependent manner. When combined with PTX, GPT synergistically causes more cell death, induces subG1 accumulation and cell apoptosis. Besides, up-regulation of BAX/BCL-2 ratio, and down-regulation of MCL-1 are also observed. Moreover, this combination inhibits IRAK1, NF-κB and ERK1/2 activation, and leads to down-regulation of inflammatory cytokines (IL6, IL8, CXCL1, CCL2), S100A7/9 and CSC-related genes (OCT4, SOX2, NANOG, ALDH1, CD44) expression. In addition, the combination treatment suppresses MB231-PR cell invasion ability, and impairs tumor sphere growth both in MB231-PR and SUM159 PTX resistant (SUM159-PR) cells. CONCLUSION: Our study demonstrates that GPT can resensitize TNBC PTX resistant cells to PTX by inhibiting the IRAK1/NF-κB and ERK pathways and reducing stem cell characteristics.
format Online
Article
Text
id pubmed-7275687
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-72756872020-06-15 Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways Wang, Panpan Song, Dan Wan, Danhong Li, Lingyu Mei, Wenhui Li, Xiaoyun Han, Li Zhu, Xiaofeng Yang, Li Cai, Yu Zhang, Ronghua PeerJ Molecular Biology BACKGROUND: Paclitaxel (PTX) resistance is a major obstacle in the treatment of triple-negative breast cancer (TNBC). Previously, we have reported that interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream pathways are associated with PTX resistance in TNBC cells. In this study, we sought to investigate the combination treatment of ginsenoside panaxatriol (GPT), one of the main active components in Panax ginseng, with PTX on viability and apoptosis of TNBC PTX resistant cells, and explore the role of IRAK1 mediated signaling pathways in the therapeutic effects. METHODS: CellTiter-Glo and colony formation assays were used to assess cell viability. Flow cytometry was used to analyze subG1 and apoptosis. Western blot was used to detect expressions of proteins involved in apoptosis and the IRAK1/NF-κB and ERK pathways. The mRNA expression of inflammatory cytokines, S100A7/8/9 and cancer stem cell (CSC)-related genes were examined by qPCR. Stem cells were identified by tumor sphere assay. Cell invasion ability was examined by transwell assay. RESULTS: We show that GPT inhibits MDA-MB-231 PTX resistant (MB231-PR) cell viability in a dose-dependent manner. When combined with PTX, GPT synergistically causes more cell death, induces subG1 accumulation and cell apoptosis. Besides, up-regulation of BAX/BCL-2 ratio, and down-regulation of MCL-1 are also observed. Moreover, this combination inhibits IRAK1, NF-κB and ERK1/2 activation, and leads to down-regulation of inflammatory cytokines (IL6, IL8, CXCL1, CCL2), S100A7/9 and CSC-related genes (OCT4, SOX2, NANOG, ALDH1, CD44) expression. In addition, the combination treatment suppresses MB231-PR cell invasion ability, and impairs tumor sphere growth both in MB231-PR and SUM159 PTX resistant (SUM159-PR) cells. CONCLUSION: Our study demonstrates that GPT can resensitize TNBC PTX resistant cells to PTX by inhibiting the IRAK1/NF-κB and ERK pathways and reducing stem cell characteristics. PeerJ Inc. 2020-06-03 /pmc/articles/PMC7275687/ /pubmed/32547883 http://dx.doi.org/10.7717/peerj.9281 Text en © 2020 Wang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Molecular Biology
Wang, Panpan
Song, Dan
Wan, Danhong
Li, Lingyu
Mei, Wenhui
Li, Xiaoyun
Han, Li
Zhu, Xiaofeng
Yang, Li
Cai, Yu
Zhang, Ronghua
Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
title Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
title_full Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
title_fullStr Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
title_full_unstemmed Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
title_short Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
title_sort ginsenoside panaxatriol reverses tnbc paclitaxel resistance by inhibiting the irak1/nf-κb and erk pathways
topic Molecular Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275687/
https://www.ncbi.nlm.nih.gov/pubmed/32547883
http://dx.doi.org/10.7717/peerj.9281
work_keys_str_mv AT wangpanpan ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT songdan ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT wandanhong ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT lilingyu ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT meiwenhui ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT lixiaoyun ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT hanli ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT zhuxiaofeng ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT yangli ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT caiyu ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways
AT zhangronghua ginsenosidepanaxatriolreversestnbcpaclitaxelresistancebyinhibitingtheirak1nfkbanderkpathways